TOKYO -- Japanese drugmaker Eisai's share price is hovering around a 10-year low of 4,300 yen, weighed down by poor U.S. sales of its much-touted Alzheimer's treatment Leqembi and the company's limited candidate portfolio concentrated in the dementia drug field.
Pharmaceuticals
Alzheimer's treatment maker Eisai's shares sink on slow U.S. sales
Biogen partner struggles to increase Leqembi recipients amid lack of facilities
Eisai's Alzheimer's drug Leqembi has been struggling to attain blockbuster status. (Eisai)
Read Next
Latest on Pharmaceuticals
